In non-human primates, an anti-CD40 mAb and a CD20 x CD3 bispecific allow AAV re-dosing

Plus: New targets involving glycosylation, angiogenesis and more

At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases

Plus: Dren Bio strikes $600M bispecific agreement with Sanofi, and more

Plus: Briumvi shows signs of growth, while sales of oral therapies remain mostly flat

How the once-dominant cancer company has overhauled its strategy for long-term growth

Companies founded in the West with Asian assets tell a story of China speed

Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset

BioCentry’s Deals Report also features AbbVie acquiring Nimble, Nvelop-Chroma forming nChroma, and BMS canceling Century, Immatics deals

How CEOs are managing through uncertainty, and why ‘boring’ naked mAbs are the smart move in one field